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ABSTRACT
Background The objective of the study was to 
identify any changes in primary percutaneous coronary 
intervention (PCI) for ST- elevation myocardial infarction 
(STEMI) in England by analysing procedural numbers, 
clinical characteristics and patient outcomes during the 
COVID-19 pandemic.
Methods We conducted a retrospective cohort study of 
patients who underwent PCI in England between January 
2017 and April 2020 in the British Cardiovascular 
Intervention Society- National Institute of Cardiovascular 
Outcomes Research database. Analysis was restricted 
to 44 hospitals that reported contemporaneous activity 
on PCI. Only patients with primary PCI for STEMI were 
included in the analysis.
Results A total of 34 127 patients with STEMI (primary 
PCI 33 938, facilitated PCI 108, rescue PCI 81) were 
included in the study. There was a decline in the number 
of procedures by 43% (n=497) in April 2020 compared 
with the average monthly procedures between 2017 
and 2019 (n=865). For all patients, the median time 
from symptom to hospital showed increased after 
the lockdown (150 (99–270) vs 135 (89–250) min, 
p=0.004) and a longer door- to- balloon time after the 
lockdown (48 (21–112) vs 37 (16–94) min, p<0.001). 
The in- hospital mortality rate was 4.8% before the 
lockdown and 3.5% after the lockdown (p=0.12). 
Following adjustment for baseline characteristics, no 
differences were observed for in- hospital death (OR 
0.87, 95% CI 0.45 to 1.68, p=0.67) and major adverse 
cardiovascular events (OR 0.71, 95% CI 0.39 to 1.32, 
p=0.28).
Conclusions Following the lockdown in England, we 
observed a decline in primary PCI procedures for STEMI 
and increases in overall symptom- to- hospital and door- 
to- balloon time for patients with STEMI. Restructuring 
health services during COVID-19 has not adversely 
influenced in- hospital outcomes.
INTRODUCTION
In response to the COVID-19 pandemic, routine 
hospital services including cardiac catheterisation 
have been restructured in order to increase hospital 
capacity for patients infected with COVID-19 and 
reduce the risk of cross- infection. This has led 
to the cancellation of some elective procedures 
and reduced access to care for patients without 
COVID-19 related disorders. Many countries have 
imposed social containment mandates, known 
as ‘lockdown’, in order to reduce the spread of 
the virus, which may have contributed to patient 
delays in seeking emergency care, because of fear 
of contracting COVID-19 at hospitals, and this has 
resulted in a reduction in cardiovascular admis-
sions.1–3 This would inevitably have important 
consequences especially in conditions such as ST- el-
evation myocardial infarction (STEMI) in which 
timely coronary revascularisation is proven to 
reduce mortality and complications.4
While there are isolated local and regional level 
reports that the COVID-19 pandemic is associated 
with a reduction in both presentations with acute 
myocardial infarction and percutaneous coronary 
intervention (PCI) procedures,5–9 there have been 
no previous data regarding its impact on national 
primary PCI rates and practices and whether there 
have been changes in either procedural or clinical 
characteristics of patients or their clinical outcomes.
Following dialogue with the Chief Scientific 
Advisor to the government of the UK, a series of 
analyses by the National Institute for Cardiovas-
cular Outcomes Research (NICOR) were endorsed 
to help inform government decision making. The 
objective of this current analysis is to identify 
the changes in primary PCI activity during the 
COVID-19 pandemic from a national perspective, 
including any changes in the clinical presentation 
and characteristics of patients and their clinical 
outcomes.
METHODS
The reporting of this cohort is in accordance with 
the recommendations of the STrengethening the 
Reporting of Observational studies in Epidemi-
ology statement.10
The British Cardiovascular Intervention Society 
(BCIS) registry contains data from all consecutive 
adults undergoing all PCI in the UK in the National 
Health Service Hospitals in England. The dataset 
has around 120 variables covering demographic 
characteristics, clinical information, periprocedural 
and outcome variables, as previously described.11–13 
BCIS has made it their mandate that all operators 
record information for all PCI procedures under-
taken, and data collection is overseen by NICOR.14
Study design, population and outcomes
We conducted a retrospective cohort study of all 
patients who underwent PCI for STEMI in England 
between 1 January 2017 and 30 April 2020 in the 
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BCIS database. Hospitals either enter data directly into a web- 
based interface provided by NICOR or upload data from their 
local database. Hospitals were encouraged to upload their data 
more frequently than usual to facilitate more contemporaneous 
analysis. To this end, they received special communications from 
both the British Cardiovascular Society and the BCIS to their 
members. In addition, staff at NICOR made direct contact with 
each hospital’s cardiovascular audit team. This project only 
included data from hospitals that successfully uploaded data on 
PCI procedures in each month of the current year until the end 
of April 2020 (by 7 May). This was necessary to ensure only 
those centres in whom all procedures had been reported and 
uploaded until the end of April were included, in order to mini-
mise the risk that we included data from centres that had failed 
to upload their most recent PCI activity. Patients not allocated 
by gender were excluded as were those who did not have PCI or 
those admitted to private hospitals, who represent less than 5% 
of PCI activity in the UK and virtually no primary PCI.
The primary outcome of interest was the number of primary 
PCI procedures for STEMI undertaken before and after the 
COVID-19 pandemic lockdown on 23 March 2020, and the 
secondary outcomes were the in- hospital mortality and major 
adverse cardiovascular events (MACE; a composite of death, 
reinfarction and unplanned re- PCI) for these procedures over the 
same period. Other in- hospital outcomes were receipt of trans-
fusion (blood or platelet), major bleeding, embolic stroke, coro-
nary perforation, retroperitoneal bleed, renal failure/dialysis and 
re- PCI. Patients who were admitted with STEMI but remained 
in hospital beyond 30 April 2020 were classified according 
to whether they had in- hospital mortality at the time of latest 
follow- up (7 May 2020). Those that remained in hospital and 
were not discharge were classed as being alive.
Covariates
Data were collected on patient demographics, comorbidities and 
treatments received (described in online supplementary data 1).
Statistical analysis
Statistical analyses were performed on Stata/MP V.16.0. We 
included patients with primary PCI for STEMI, facilitated PCI 
for STEMI and rescue PCI for STEMI in the cohort, but only 
those with primary PCI for STEMI were included in the analysis. 
The cohort was divided into patients who underwent primary 
PCI for STEMI in 2017–2019 and those who had a primary PCI 
procedure performed from 1 January to 30 April 2020. For the 
analysis of trend, the monthly average PCI procedures for the 
years 2017, 2018 and 2019 were determined, and these averages 
were compared against the number of procedures in each month 
in 2020. The date of the UK lockdown was 23 March 2020 and 
was marked in the figures between the months March and April 
2020. Descriptive statistics are presented by whether primary 
PCI took place before or after the lockdown. Median values and 
IQRs for continuous variables and the number and percentages for 
categorical variables were reported. Using all patients admitted 
in 2017–2019 as a reference group, the Mann- Whitney test for 
continuous variables and χ2 test for categorical variables were 
used to determine if there was any statistical difference in patient 
characteristics, procedural variables and in- hospital outcomes 
after and before the lockdown. Figures were used to show timing 
from symptom- to- hospital and door- to- balloon as well as in- hos-
pital death and MACE before and after the lockdown. This was 
done for the overall primary PCI cohort for STEMI as well as 
the subgroups that were admitted to the PCI centre directly from 
the community and those that were transferred to the PCI centre 
from another hospital. Multiple logistic regression models were 
used to evaluate the independent odds of in- hospital mortality 
and MACE. This model was adjusted for all covariates previ-
ously mentioned, except for left ventricular function, smoking 
status and ethnicity because of the extent of missing data for 
these variables. Additional analyses were performed where the 
mi impute chained function was used to generate 10 complete 
datasets to account for missing data. Multiple logistic regres-
sions were then conducted to evaluate the independent odds of 
in- hospital mortality, and MACE were performed with adjust-
ments all variables including left ventricular function, smoking 
status and ethnicity. Finally, the descriptive statistics were also 
presented in tables stratified by indication for PCI. A sensitivity 
analysis was performed restricting the control group to the same 
months of January–April in the calendar years 2017, 2018 and 
Figure 1 Flow diagram of patient inclusion. BCIS, British 
Cardiovascular Intervention Society; NICOR, National Institute of 
Cardiovascular Outcomes Research; PCI, percutaneous coronary 
intervention; STEMI, ST- elevation myocardial infarction.
Figure 2 Rate of primary percutaneous coronary intervention (PCI) for 
ST- elevation myocardial infarction (STEMI) over time.
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2019 in order to avoid any potential issues related to seasonal 
differences in the numbers of procedures.
RESULTS
A total of 34 127 patients undergoing PCI with STEMI were 
included in the analysis (figure 1). The list of hospitals included 
in the analysis is shown in the online supplementary data 2. This 
includes STEMI patients undergoing primary PCI (n=33 938), 
facilitated PCI (n=108) and rescue PCI (n=81). The missing 
data for the cohort of patients with STEMI who underwent 
primary PCI is shown in online supplementary table 1.
The numbers of primary PCI for STEMI over time is illus-
trated in figure 2. A 43% decline in monthly average procedures 
was recorded between 2017 and 2019 (865) to 497 in April 
2020. The changes in rescue and facilitated PCI for STEMI is 
shown in online supplementary figure 1, and there were no clin-
ically significant increases.
The characteristics according to month are shown in online 
supplementary table 2. Compared with 2017–2019, patients 
admitted with primary PCI for STEMI in the month of April 
2020 were more likely to have radial access (89.1% vs 83.9%, 
p=0.002), multivessel PCI (16.9% vs 12.8%, p=0.007) and 
have longer time from symptom- to- hospital (median 135 min vs 
153 min, p=0.004) and door- to- balloon time (median 37 min vs 
48 min, p<0.001).
The percentage difference comparing the number of proce-
dures after and before the lockdown was not consistent across 
all primary PCI volume centres as there was a decline of 20.4%, 
25.9%, 11.1% and 56.8% across the quartiles 1, 2, 3 and 4 based 
on volume of primary PCI. It appears that the largest decline 
was observed in highest volume centres. The patient characteris-
tics for primary PCI prelockdown and postlockdown are shown 
in table 1. Patients postlockdown had a greater proportion of 
multivessel intervention (16.0% vs 12.7%, p=0.012) with an 
increased use of prasugrel (12.9% vs 6.4%, p<0.001), with a 
decline in clopidogrel (11.0% vs 21.5%, p<0.001), ticagrelor 
(41.0% vs 48.6%, p<0.001), glycoprotein IIb/IIIa inhibitor 
(22.6% vs 27.7%, p=0.003) use.
The characteristics of patients according to direct admission 
from community compared with transfer from another hospital 
are shown in online supplementary table 3 and transferred 
patients were younger (62 vs 64 years, p<0.001) and a greater 
proportion were male (76.6% vs 74.3%, p<0.001), of non- 
Caucasian ethnicity (19.3% vs 13.4%, p<0.001) and had out- 
of- hours PCI (57.9% vs 53.3%, p<0.001).
The time from symptom to hospital and from door to balloon 
before and after lockdown are shown in figure 3. For all patients, 
Table 1 Patient characteristics for patients who underwent primary 
PCI for ST- elevation myocardial infarction according to those who are 






Median age (IQR) 63 (55–73) 64 (55-72) 0.45
Male, n (%) 24 829 (74.7) 498 (72.9) 0.30
Ethnicity, n (%) 0.30
  Caucasian 23 893 (85.8) 482 (84.3)
  Black, Asian or other 3952 (14.2) 90 (15.7)
Smoker, n (%) 7869 (40.9) 148 (38.1) 0.26
Hypertension, n (%) 13 826 (43.2) 234 (39.4) 0.067
Hypercholesterolaemia, n (%) 11 186 (34.9) 195 (32.8) 0.29
Diabetes mellitus, n (%) 6006 (18.5) 107 (16.4) 0.16
Left ventricular function, n (%) 0.95
  Good 4289 (44.0) 79 (45.1)
  Fair/moderate 4350 (44.6) 76 (43.4)
  Poor 1109 (11.4) 20 (11.4)
Renal failure, n (%) 0.42
  None 30 192 (98.1) 579 (98.0)
  Acute renal failure 439 (1.4) 11 (1.9)
  Chronic renal failure 136 (0.4) 1 (0.2)
Previous MI, n (%) 4046 (12.4) 72 (11.4) 0.43
Previous stroke, n (%) 1220 (3.8) 16 (2.7) 0.16
Previous PCI, n (%) 4081 (12.5) 75 (11.8) 0.60
Previous CABG, n (%) 787 (2.4) 15 (2.3) 0.92
Peripheral vascular disease, 
n (%)
898 (2.8) 10 (1.7) 0.10
Valvular heart disease, n (%) 62 (2.0) 4 (0.7) 0.024
Radial access, n (%) 27 917 (84.0) 611 (89.5) <0.001
Multivessel intervention, n (%) 4229 (12.7) 109 (16.0) 0.012
Vessel of intervention, n (%)
  Left main 917 (2.8) 17 (2.5) 0.67
  RCA 13 982 (42.0) 282 (41.3) 0.69
  LAD 14 683 (44.2) 308 (45.1) 0.62
  LCx 5881 (17.7) 143 (20.9) 0.028
  Graft 348 (1.1) 8 (1.2) 0.75
Medications, n (%)
  Clopidogrel 7160 (21.5) 75 (11.0) <0.001
  Ticagrelor 16 165 (48.6) 280 (41.0) <0.001
  Prasugrel 2130 (6.4) 88 (12.9) <0.001
Glycoprotein IIb/IIIa inhibitor 9195 (27.7) 154 (22.6) 0.003
Imaging (OCT/IVUS), n (%) 2348 (7.1) 52 (7.6) 0.58
Rotational atherectomy, n (%) 71 (0.2) 1 (0.2) 0.71
IABP, n (%) 625 (1.9) 2 (0.3) 0.002
ECMO/impella, n (%) 19 (0.06) 1 (0.2) 0.34
Cardiogenic shock, n (%) 2474 (7.4) 42 (6.2) 0.20
Inotropes, n (%) 1333 (4.0) 19 (2.8) 0.11
Thrombectomy device use, 
n (%)
5142 (15.5) 84 (12.3) 0.023
Number of stents, n (%) 0.38
  0 3460 (10.4) 61 (8.9)
  1 18 950 (57.0) 405 (59.3)
  2 7568 (22.8) 158 (23.1)
  3+ 3277 (9.9) 59 (8.6)
TIMI 3 flow post procedure, 
n (%)
26 598 (84.6) 559 (89.6) 0.001
Route, n (%) 0.010
  Direct from community 27 014 (81.2) 579 (84.8)
  Hospital transfer 5375 (16.2) 82 (12.0)







Median time from symptom to 
hospital (IQR)
135 (89–250) 150 (99–270) 0.004
Median time from door to 
balloon (IQR)
37 (16–94) 48 (21–112) <0.001
Out- of- hours symptom onset, 
n (%)
19 744 (60.9) 372 (60.7) 0.92
Out- of- hours PCI, n (%) 17 949 (54.0) 367 (54.7) 0.90
*Mann- Whitney test for continuous variables and χ2 test for categorical variables.
CABG, coronary artery bypass graft; ECMO, extracorporeal membrane oxygenation; IABP, 
intra- aortic balloon pump; IVUS, intravascular ultrasound; LAD, left anterior descending; 
LCx, left circumflex; MI, myocardial infarction; OCT, optical coherence tomography; PCI, 
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the time from symptom to hospital was greater after the lock-
down (median 150 min vs 135 min, p=0.004) and the door- 
to- balloon time was also greater after the lockdown (median 
48 min vs 37 min, p<0.001). The increase in time from symptom 
to hospital was observed after lockdown for the subgroup of 
patients admitted directly from community (median 145 min 
vs 135 min, p=0.020) as well as those that were transferred 
between hospitals (median 239 min vs 235 min, p=0.045). The 
door- to- balloon time was also greater after the lockdown for 
patients admitted directly from the community (median 41 min 
vs 28 min, p<0.001) but not statistically different for those with 
hospital transfer (median 185 min vs 143 min, p=0.13).
Crude in- hospital patient outcomes prelockdown and post-
lockdown are shown in table 2 and figure 4. No significant 
differences in mortality were observed overall (3.5% vs 4.8%, 
p=0.12), but in- hospital MACE was significantly reduced post-
lockdown (3.5% vs 5.5%, p=0.022), and there was a shorter 
median length of stay postlockdown (2 days vs 3 days, p<0.001). 
Similar patterns were observed for patients who were admitted 
directly from the community (2.6% vs 4.7%, 2.6% vs 5.5%, 
respectively). For patients who were transferred from another 
hospital, there was an increase in both in- hospital death (7.5% 
vs 4.5%) and MACE (7.3% vs 5.1%).
The adjusted odds of in- hospital death and MACE are shown 
in table 3. No differences were observed for both outcomes 
overall (OR 0.87, 95% CI 0.45 to 1.68, p=0.67 and OR 0.71, 
95% CI 0.39 to 1.32, p=0.28, respectively) or in the subgroups 
according to direct or interhospital admission. After imputa-
tions for missing data, the analysis adjusted additionally for left 
ventricular function, ethnicity and smoking status and similarly 
showed no significant differences in in- hospital outcomes.
The sensitivity analysis only including the months of January–
April for the calendar years 2017–2019 are shown in online 
supplementary figure 2 and online supplementary table 4. The 
results are largely similar to those reported in the overall analysis.
DISCUSSION
Our evaluation to describe national cases of primary PCI activity 
for STEMI during the COVID-19 pandemic has several key find-
ings. First, the decline in number of cases of primary PCI for 
STEMI started before the lockdown on the 23 March 2020, and 
there was a 43% decrease by the end of April 2020. Second, the 
lockdown was associated with increases in symptom- to- hospital 
time and door- to- balloon time. Third, after the lockdown, the 
difference in time from symptom to hospital and door to balloon 
was greatest for patients who underwent hospital transfer. 
Finally, once differences in baseline characteristics were adjusted 
for, there were no differences in clinical outcomes (mortality 
and MACE) before and after lockdown. These findings suggest 
that primary PCI for STEMI has declined after the national lock-
down in England but restructuring of hospital services during the 
COVID-19 pandemic has not adversely compromised in- hos-
pital outcomes for patients having these procedures.
Our results support the decline in primary PCI procedures for 
STEMI reported in other studies, but we add some additional 
value to such observations by describing clinical and procedural 
characteristics and clinical outcomes after the COVID-19 lock-
down using previous years as a reference. During the early phase 
of COVID-19 pandemic, there was an estimated 38% reduction 
in US cardiac catheterisation laboratory STEMI activations from 
nine high- volume centres.8 Another survey of 73 centres in Spain 
reported a 40% reduction in procedures performed in the STEMI 
settings.9 We report a 43% reduction in all STEMI- related PCI 
procedures (including primary, rescue and facilitated) in England 
in the month after the lockdown. Importantly, our paper shows 
that patients undergoing primary PCI were not at increased odds 
Figure 3 Median time to from symptom- to- hospital and door- to- 
balloon time percutaneous coronary intervention (PCI) prelockdown and 
postlockdown.
Table 2 Patient outcomes for patients who underwent primary PCI 
for ST- elevation myocardial infarction according to those who are 






Transfusion, n (%) 75 (0.2) 2 (0.3) 0.71
Major bleeding, n (%) 69 (0.2) 3 (0.4) 0.19
Death, n (%) 1590 (4.8) 23 (3.5) 0.12
MACE (death, reinfarction and 
PCI), n (%)
1841 (5.5) 24 (3.5) 0.022
Embolic stroke, n (%) 53 (0.2) 0 (0) 0.30
Coronary perforation, n (%) 78 (0.2) 2 (0.3) 0.76
Retroperitoneal bleed, n (%) 10 (0.03) 2 (0.30) <0.001
Renal failure/dialysis, n (%) 78 (0.2) 1 (0.2) 0.64
Re- PCI, n (%) 236 (0.7) 1 (0.2) 0.080
Median length of stay (IQR) 3 (2–4) 2 (1–3) <0.001
PCI, percutaneous coronary intervention.
Figure 4 In- hospital mortality and major adverse cardiovascular 
events (MACE) prelockdown and postlockdown.
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of in- hospital death and MACE compared with patients before 
the lockdown period.
There are several explanations why there may be a decrease in 
primary PCI for STEMI during the COVID-19 pandemic. One 
possibility is that there was a lower incidence of STEMI during 
the outbreak, but this is unlikely. A more convincing expla-
nation is that lower rates of STEMI relate to multiple factors 
including avoidance of medical care or concerns over contracting 
COVID-19 in hospital, misdiagnosis and increased use of phar-
macological reperfusion due to COVID-19.8 In England, there 
were clear government recommendations to ‘stay at home and 
protect the National Health Service (NHS)’ which may have 
created an atmosphere of fear of contracting COVID-19 by 
leaving the home and going to hospital. The consequences of 
not seeking medical care following a STEMI may be significant; 
for example, a 58% increase in out- of- hospital cardiac arrests 
was observed between February and March 2020 compared with 
2019 in the Lombardia Cardiac Arrest Registry.15 In addition, 
a reduction in primary PCI activity may be related to reduced 
catheter laboratory capacity due to staff sickness and redeploy-
ments as well as the need for deep cleaning between cases as 
these were important factors highlighted in a survey of 43 UK 
primary PCI centres.16
While our findings suggest that there are fewer patients 
receiving primary PCI, we have shown that the COVID-19 
pandemic does not appear to have compromised overall in- hos-
pital clinical outcomes. Our study provides further insight 
regarding delays to PCI during the COVID-19 pandemic. Specif-
ically, we found evidence of prolonged symptom- to- hospital 
time after the COVID-19 lockdown in England. This is consis-
tent with the findings from a study of the management of STEMI 
in Hong Kong reporting a median of 318 min from symptom 
onset to first medical contact for seven patients since January 
2020 compared with 82 min during office hours in 2018–2019 
for 48 patients and a prolonged door- to- device time of 110 min 
compared with 84 min, respectively.4 We have furthered what is 
known by identifying that the delays were greatest for patients 
who required interhospital transfer that may relate to hospital 
COVID-19 policies that delay transfers between hospitals. It is 
possible that ambulance services have been busier and occupied 
with the burden of patients with suspected COVID-19, which 
further contributed to this delay. We also report an increase in 
delay from door to balloon after the lockdown, which is likely 
multifactorial. During the COVID-19 pandemic, UK government 
recommended cancellation of elective procedures,17 allowing 
hospital services to be restructured to divert more hospital staff 
and infrastructure to increase capacity for the treatment of 
COVID-19, reduce the exposure of individual patients and their 
relatives to the hospital environment and reduce the exposure 
of healthcare workers to asymptomatic patients with COVID-
19. Furthermore, catheter laboratory staff were redeployed to 
other intensive care environments and that consequently may 
have decreased catheter lab capacity, introducing delays particu-
larly if more than one STEMI call is activated. Furthermore, new 
and more intensive evaluation prior to the angiogram procedure 
due to activities such as chest X- ray and other assessments to 
ascertain the potential risk of COVID-19 infection, as well as 
the additional time required to ensure that staff to ‘don’ personal 
protective equipment may have further contributed to delays.
A few other observations can be made about the population 
receiving PCI before and after the COVID-19 lockdown. We 
observed that patients presenting after the lockdown were more 
likely to receive multivessel PCI. This may reflect recent data 
from the Complete Revascularization with Multivessel PCI for 
Myocardial Infarction (COMPLETE) trial that patients with 
STEMI and multivessel coronary artery disease had lower rates 
of cardiovascular death and myocardial infarction with complete 
compared with culprit only revascularisation.18 However, it may 
also relate to the operator awareness that since elective activity 
stopped during peak the COVID-19 outbreak, patients with 
bystander disease discharged with culprit only PCI may be put 
at a disadvantage in terms of elective access for staged complete 
revascularisation within 45 days, as used in COMPLETE.
An important consideration around primary PCI services 
for STEMI during the COVID-19 pandemic is how changes in 
patient’s health- seeking behaviour, health service delivery and 
government strategies in mitigating the impact of the pandemic 
may impact the characteristics of patients that receive treat-
ment and their associated clinical outcomes. Fear of contracting 
COVID-19 and messages from government about self- isolation 
and avoiding hospitals unless absolutely necessary may result in 
patients not seeking or delay seeking medical attention. In the 
Table 3 Multivariable odds of major adverse cardiovascular events (MACE) and in- hospital death for patients prelockdown and postlockdown who 
underwent primary percutaneous coronary intervention for ST- elevation myocardial infarction
Group
Comparison of postlockdown versus prelockdown
No imputations Imputed dataset
Adjusted OR (95% CI)* P value Adjusted OR (95% CI)† P value
Overall
  MACE 0.71 (0.39 to 1.32) 0.28 0.78 (0.50 to 1.24) 0.29
  In- hospital death 0.87 (0.45 to 1.68) 0.67 0.94 (0.58 to 1.52) 0.80
Direct from community
  MACE 0.66 (0.33 to 1.30) 0.23 0.63 (0.36 to 1.10) 0.10
  In- hospital death 0.77 (0.37 to 1.63) 0.50 0.74 (0.41 to 1.33) 0.31
Transfer
  MACE 0.88 (0.16 to 5.02) 0.89 1.39 (0.50 to 3.86) 0.52
  In- hospital death 1.18 (0.20 to 7.10) 0.86 1.86 (0.66 to 5.28) 0.24
*Adjusted for age, sex, hypertension, hypercholesterolaemia, diabetes mellitus, renal disease, previous myocardial infarction, previous stroke, previous percutaneous coronary 
intervention, previous coronary artery bypass graft, peripheral vascular disease, valvular heart disease, radial access, multivessel disease, vessel of intervention, medications, 
glycoprotein IIb/IIIa inhibitor use, imaging, rotational atherectomy, intra- aortic balloon pump, extracorporeal membrane oxygenation/impella, cardiogenic shock, inotropes, 
number of stents, flow, thrombectomy, symptom- to- hospital time, door- to- balloon time, out- of- hours symptoms and out- of- hours percutaneous coronary intervention.
†Adjusted for all variables in * and left ventricular function, ethnicity and smokers.
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context of STEMI, this could manifest itself as increase in number 
of out- of- hospital cardiac arrest that has been observed in Italy 
and France.15 19 It is important to recognise that the patients eval-
uated in the current study are those that underwent primary PCI, 
but there may be patients who had STEMI who did not undergo 
PCI such as those who had an out- of- hospital cardiac arrest and 
died, or those that chose not seek medical attention, or those 
that presented late where the infarct was completed and there 
would be little benefit to PCI. We observed an increase in the use 
of prasugrel and a decrease in use of ticagrelor and clopidogrel 
after the lockdown. This is likely because of the changes in prac-
tice in response to the Intracoronary Stenting and Antithrom-
botic Regimen: Rapid Early Action for Coronary Treatment 5 
trial,20 which found that death, myocardial infarction and stroke 
were lower among patients with prasugrel compared with tica-
grelor. While not statistically significant, there were a greater 
proportion of patients with previous stroke in the group before 
compared with after the lockdown. Prasugrel is contraindicated 
in patients with previous stroke, and this may partly explain why 
there may be an increase use of prasugrel postlockdown.
Our study has several limitations. First, not all hospitals in 
England were included in the analysis because they did not 
report their PCI activity in either March or April 2020. It 
was important to exclude these hospitals that had so far not 
submitted, because the decline in PCI activity could be incor-
rectly attributed to failure of timely data submission rather than 
fewer cases. Second, in- hospital outcomes are self- reported and 
together with early discharge may have result in under- reporting 
of adverse outcomes. There is no postdischarge follow- up data, 
and there were missing data particularly regarding left ventric-
ular ejection fraction and smoking status that may confound 
multivariate adjustment. Nevertheless, the data are subject to 
logical checks and assessments of internal validity at upload to 
NICOR. Additionally, the decline in PCI activity that we have 
observed is in line with that reported in Spain and the USA.8 9 
Finally, there is no understanding of how local policies at each 
hospital may have changed as a result of the COVID-19 crisis, 
which may be driving the decline in procedures.
In conclusion, our national evaluation demonstrates a 43% 
decrease in PCI activity following the COVID-19 response 
lockdown. Although symptom- to- hospital and door- to- balloon 
times were increased after the lockdown, we did not demon-
strate any differences in adverse in- hospital patient outcomes 
after the lockdown.
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